Dr Lisa Campbell

Dr Lisa Campbell leads the regulatory, pharmacovigilance and medical writing functions at Richmond Pharmacology. She is responsible for guiding regulatory strategy across all clinical studies, overseeing submissions, supporting regulatory engagements with UK, EU and international authorities, and ensuring the delivery of high-quality, compliant pharmacovigilance services.

Lisa is also Chair of Richmond's External Regulatory Advisory Board (ERAB), where she works with an international panel of experts to provide strategic regulatory insight and support the development of innovative medicines.

She brings over two decades of experience in drug development, clinical medicine and regulatory science. Lisa previously held senior consultancy positions at NDA Regulatory Science and SSI Strategy, where she advised on global clinical programmes for advanced therapies, gene editing and rare diseases.

During her nine years at the MHRA, Lisa was a Senior Medical Assessor in the Clinical Trials Unit. Her work included helping to develop the Innovative Licensing and Access Pathway (ILAP), shaping patient and public involvement strategies, and leading assessments for first-in-human and adaptive platform trials.

Originally trained in Obstetrics and Gynaecology, Lisa holds an MD in Diabetes in Pregnancy and has developed particular expertise in women's health and addressing the female data gap in clinical research. She is a recognised advocate for improving the representation of women in clinical trials and ensuring regulatory frameworks support more inclusive evidence generation.

Lisa is a Fellow of the Faculty of Pharmaceutical Medicine (FFPM) and is widely published in journals including Nature Medicine, BMJ Open and JAMA. Her expertise spans regulatory strategy, pharmacovigilance, clinical trial design and policy development.

At Richmond Pharmacology, Lisa is focused on delivering innovative, inclusive and compliant regulatory solutions that help clients accelerate drug development, improve patient access to new therapies and advance more diverse and representative clinical research.

‍